Arrowhead Research | ARWR - Capital Social Ordinario





Capital Social Ordinario Cambio Fecha
Agios Pharmaceuticals USD 59.34M 892K 2026-03
Alnylam Pharmaceuticals USD 133.73M 290K 2026-06
Anika Therapeutics USD 13.89M 532K 2025-12
Arrowhead Research USD 141.14M 564K 2026-06
Heron Therapeutics USD 188.31M 4.99M 2025-12
Incyte USD 200.98M 1.03M 2026-06
Ionis Pharmaceuticals USD 165.64M 265K 2026-06
Ligand Pharmaceuticals USD 19.66M 19.64M 2025-09
Merck USD 2.47B 4.93M 2026-03
Moderna USD 391M 2M 2025-09
Nektar Therapeutics USD 29.47M 9.09M 2026-03
Novartis USD 1.9B 7.38M 2026-06
Sarepta Therapeutics USD 105.62M 53K 2026-06
TG Therapeutics USD 153.08M 2.23M 2026-06
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Vertex Pharmaceuticals USD 253.3M 900K 2026-06
Xencor USD 74.33M 265K 2026-06